Cargando…

Comparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide Inhibition

SIMPLE SUMMARY: Mass spectrometry-based proteomic analysis of the VCaP prostate cancer cells treated with androgen and the androgen receptor (AR) signaling inhibitor darolutamide revealed a generally good agreement with transcriptomic responses. In some cases, however, the magnitude of changes induc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nevedomskaya, Ekaterina, Sugawara, Tatsuo, Baumgart, Simon J., Lesche, Ralf, Hahne, Hannes, Mumberg, Dominik, Haendler, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817687/ https://www.ncbi.nlm.nih.gov/pubmed/36611998 http://dx.doi.org/10.3390/cancers15010002

Ejemplares similares

Darolutamide antagonizes androgen signaling by blocking enhancer and super‐enhancer activation
por: Baumgart, Simon J., et al.
Publicado: (2020)

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
por: Sugawara, Tatsuo, et al.
Publicado: (2019)

Recent Advances in Prostate Cancer Treatment and Drug Discovery
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2018)

Dysregulated Transcriptional Control in Prostate Cancer
por: Baumgart, Simon J., et al.
Publicado: (2019)

Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
por: Hammer, Stefanie, et al.
Publicado: (2021)

From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide
por: Podgoršek, Eva, et al.
Publicado: (2023)

BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients
por: Sugawara, Tatsuo, et al.
Publicado: (2016)

Darolutamide for prostate cancer
Publicado: (2020)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment
por: Zurth, Christian, et al.
Publicado: (2021)

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
por: Lallous, Nada, et al.
Publicado: (2021)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Exploiting Epigenetic Alterations in Prostate Cancer
por: Baumgart, Simon J., et al.
Publicado: (2017)

Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target
por: Brzezinka, Krzysztof, et al.
Publicado: (2020)

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents
por: Klingbeil, Olaf, et al.
Publicado: (2016)

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
por: Brzezinka, Krzysztof, et al.
Publicado: (2019)

Targeting fatty acid oxidation via Acyl-CoA binding protein hinders glioblastoma invasion
por: Duman, Ceren, et al.
Publicado: (2023)

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
por: Kumar, Naveen
Publicado: (2022)

Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells
por: Gupta, Siddharth, et al.
Publicado: (2020)

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
por: Zurth, Christian, et al.
Publicado: (2019)

Selective Sensing of Darolutamide and Thalidomide in Pharmaceutical Preparations and in Spiked Biofluids
por: Talaat, Wael, et al.
Publicado: (2022)

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
por: Scott, Lesley J.
Publicado: (2020)

Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer
por: Crawford, E David, et al.
Publicado: (2020)

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
por: Scott, Lesley J.
Publicado: (2022)

Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer
por: Appukkuttan, Sreevalsa, et al.
Publicado: (2021)

Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Mori, Keiichiro, et al.
Publicado: (2020)

Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison
por: Chowdhury, Simon, et al.
Publicado: (2021)

Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2015)

The fate of the duplicated androgen receptor in fishes: a late neofunctionalization event?
por: Douard, Véronique, et al.
Publicado: (2008)

Androgen receptor profiling predicts prostate cancer outcome
por: Stelloo, Suzan, et al.
Publicado: (2015)

YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy
por: Lam, Wing, et al.
Publicado: (2023)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model
por: Suominen, Mari I., et al.
Publicado: (2023)

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_68rn2ah4qpje2o95eoiu7ac3d3